Cash and cash equivalents were $213.2 million as of December 31, 2025, which is anticipated to fund operations into 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO:
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts
- Crescent Biopharma announces grants of inducement awards
- Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target
- Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
- Crescent Biopharma initiated with an Overweight at Piper Sandler